New drug cocktail targets tough KRAS G12D cancers in early trial
NCT ID NCT06385678
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tests a new drug called HRS-4642 combined with several other anti-cancer medicines in 47 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check safety, find the best dose, and see if the combination can shrink tumors. Participants must have tumors that cannot be removed by surgery and have already spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-4642 combined with other anti-cancer drugs (adebrelimab, SHR-9839, pemetrexed, cisplatin, carboplatin, cetuximab)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat cancers that have a specific KRAS G12D mutation.
- What could go wrong
- This is an early-phase trial with only 47 participants, so results may not apply to everyone. The combination drugs may cause significant side effects, and the treatment may not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, 200120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.